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Abstract
Background: We previously showed that B-cell receptor (BCR) signaling pathways are important for in vitro survival
of mantle cell lymphoma (MCL) cells. To further identify early BCR-activated signaling pathways involved in MCL cell
survival, we focused our study on BCR-proximal kinases such as LYN whose dysregulations could contribute to the
aggressive course of MCL.
Methods: Primary MCL cells were isolated from 14 leukemic patients. Early BCR-induced genes were identified by
qRT-PCR array. The basal and BCR-induced phosphorylation of LYN and JNK were evaluated by immunoblottting.
Cell survival signals were evaluated by apoptosis using flow cytometry.
Results: We showed that LYN was constitutively phosphorylated in MCL cell lines and in 9/10 leukemic MCL cases.
Treatment with dasatinib or with a specific inhibitor of Src kinases such as PP2 suppressed constitutive LYN
activation and increased in vitro spontaneous apoptosis of primary MCL cells. BCR engagement resulted in an
increase of LYN phosphorylation leading to activation of c-JUN NH2-terminal kinase (JNK) and over-expression of
the early growth response gene-1 (EGR-1). Inhibition of JNK with SP600125 induced apoptosis and reduced level of
basal and BCR-induced expression of EGR-1. Furthermore, decreasing EGR1 expression by siRNA reduced BCR-
induced cell survival. Treatment with PP2 or with dasatinib suppressed BCR-induced LYN and JNK phosphorylation
as well as EGR-1 upregulation and is associated with a decrease of cell survival in all cases analysed.
Conclusions: This study highlights the importance of BCR signaling in MCL cell survival and points out to the
efficiency of kinase inhibitors in suppressing proximal BCR signaling events and in inducing apoptosis.
Keywords: Mantle cell lymphoma, LYN, BCR, EGR-1, Dasatinib
Background
Mantle cell lymphoma (MCL) constitutes about 6%–10%
of non-Hodgkin lymphoma and despite recent advances
in the treatment, the disease has not generally been
cured with a poor progression-free survival for a large
number of patients. New therapies that target specific
signaling molecules are therefore of potential value. In
recent years, some studies tried to reveal new suitable
therapeutic targets [1-9] and have clarified the impact
of several signaling pathways for increased proliferation
and resistance to apoptosis of MCL cells. Constitutively
active B-cell receptor (BCR)-mediated signaling has
been implicated in the pathogenesis of a number of
NHLs including diffuse large B cell lymphoma (DLBCL),
follicular lymphoma, gastric mucosa-associated lymph-
oid tissue lymphoma and B-cell chronic lymphocytic
leukaemia (CLL) [10-13]. Recently, we demonstrated
in primary MCL cells a central role for active BCR
signals in survival of MCL cells [14]. The activated
forms of the BCR-associated kinases LYN and spleen
tyrosine kinase (SYK) were present in MCL tumor
tissues therefore supporting an in vivo role of active
BCR signaling in this pathology [15]. Moreover, MCL
is characterized by a highly restricted immunoglobulin
gene repertoire with stereotyped VH CDR3s and
precise Somatic Hyper Mutation targeting, thus strongly
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implying a role for antigen-driven selection of the
clonogenic progenitors [16].
Upon antigen engagement, Igα–Igβ heterodimer
(CD79a-CD79b) are phosphorylated on immunoreceptor
tyrosine-based activation motif (ITAM) tyrosines by the
BCR-associated kinase LYN, which belongs to the Src
family kinases (SFK). SYK protein is then recruited
through its SH2 domain to the phosphorylated Igα–Igβ
heterodimer, resulting in the triggering of different sig-
naling cascades [17]. Among them, the PLCγ2/PKC
pathway is crucial for activation of various mitogen-
activated protein kinases (MAPKs), such as extracellular
signal-regulated kinase (ERK) and c-JUN NH2-terminal
kinase (JNK). Extensive work by several groups has
established that MAP kinase pathways play critical roles
in the pathogenesis of various hematologic malignancies,
providing new potential molecular targets for future
therapeutic approaches [18]. Indeed, gene expression
profiling of DLBCL revealed enhanced expression of
JNK mRNA in at least 60 percent of cases [19]. More-
over inhibition of JNK activation by the pharmacological
inhibitor SP600125 induced growth arrest in myeloma
cell lines [20]. Of interest, JNK was showed to be consti-
tutively activated in MCL and inhibition of phospho-
JNK with SP600125 resulted in growth arrest in MCL
cell lines (Jeko-1, HBL-2, UPN-1, Granta-519) [21].
A key downstream target of JNK activation is the early
growth response gene-1 (EGR-1) transcription factor
playing an important role in cell cycle regulation, cell
proliferation and apoptosis [22,23]. EGR-1 was first iden-
tified as a putative G0/G1 switch regulatory gene in
lymphocyte cultures [24]. Constitutive EGR-1 expres-
sion is involved in the self-renewal capacity of B-1
lymphocytes [25] and hematopoietic stem cells [26].
EGR-1 is also constitutively expressed in immature BKS-
2 B lymphoma and inhibition of EGR-1 using specific
antisense oligonucleotides induced apoptosis [22]. Alter-
natively, mature B2 cells undergo proliferation with an
increase of EGR-1 expression upon BCR engagement
[25]. Moreover, EGR-1 is down-regulated upon JNK in-
hibition by SP600125, and its overexpression partially
protects against JNK inhibitor-induced apoptosis in B
lymphoma cell lines [27].
Given the importance of BCR signaling in tumor cell sur-
vival including MCL cells, we hypothesized that targeting
BCR-associated kinases such as SFK represents a potentially
useful strategy to treat MCL. LYN kinase is the major SFK
expressed in B cells and its constitutive phosphorylation was
previously reported in Jeko-1 cell line [28]. However its role
in MCL has not yet been explored to date. Therefore we
analysed the activation status of LYN in primary MCL cells
and evaluated the in vitro impact of its inhibition on MCL
cells survival. We showed that LYN was constitutively
phosphorylated in most MCL cases tested and that BCR
engagement led to an increased LYN phosphorylation.
Treatment with dasatinib, the oral broad inhibitor of tyro-
sine kinases, suppressed BCR-induced LYN and JNK phos-
phorylation in primary MCL cells. Similarly, treatment with
dasatinib inhibited BCR-dependent EGR-1 upregulation and
cell survival. Using PP2, a more specific inhibitor of BCR-
associated SFK, we proved the efficiency of blocking BCR-
emanating signals in suppressing MCL cell survival.
Results
EGR-1 and c-MYC are rapidly induced upon BCR
engagement in MCL
We have previously described that BCR engagement
induces a survival signal in MCL through an IL6/IL10-
dependent activation-loop of STAT3 [14]. To further
investigate which BCR-induced signaling pathways are
critical, we screened purified B cells from primary
leukemic MCL for the differential expression of
84 genes upon anti-IgM stimulation using RT2 Profiler
PCR Arrays (SA Biosciences PAHS-027). Fifteen genes
exhibited significant increased or decreased expression
as compared to unstimulated cells (Additional file 1:
Table S2; average fold-change from 4 individual
experiments using UPN 5, 10, 13 and 14). Four genes
were down-regulated (APAF1, CCNG2, ATM, BTG2), all
corresponding to proapoptotic proteins. Conversely,
eleven genes were overexpressed (CDK4, MCL1, NFkB1,
IFNB1, SESN2, BCL2A, IL6, TNF, HK2, EGR-1, c-MYC),
all of them being involved in cell cycle progression or in-
hibition of apoptosis. Within this group, three genes
encoded for transcription factors; namely NF-kB, c-MYC
and EGR-1 the two later being the two most upregulated
genes upon anti-IgM stimulation (average of 23.6- and
17.6-fold increase, respectively).
BCR-induced expressions of c-MYC and EGR-1 were then
confirmed by kinetic experiments in MCL cell lines
(Granta-519 and HBL-2) (Figure 1A and B) and in MCL
patients’ samples (Figure 1C). For MCL cell lines, basal
levels of EGR-1 mRNA was rapidly increased within 30 min
upon BCR ligation, peaked at 1 h and gradually returned to
basal level within 3 to 6 hours. Similarly, EGR-1 protein
levels increased upon anti-IgM stimulation and returned to
basal level within 6 h (Figure 1B). A similar increase was
observed for primary cells (UPN7 and UPN10) with EGR-1
proteins still detectable at 6 hours (Figure 1C). C-MYC ex-
pression was significantly induced upon BCR engagement in
patients’ cells only (Figure 1A for Granta-519 and HBL-2
cells, Figure 1C for UPN7). The pattern of c-MYC mRNA
induction differed from that of EGR-1 and displayed a con-
stant increase at least up to 3 h associated with an increase
of c-MYC protein (Figure 1C). We next evaluated the im-
pact of BCR stimulation on a series of 7 patients’ samples
(Figure 1D). Upon 1 h of anti-IgM stimulation, EGR-1
mRNA expression was highly upregulated in 4 out of 7 cases
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and clearly with a major extent as compared to induction of
c-MYC (median fold increase: 30.1 and 2.98 for EGR-1 and
c-MYC respectively). No correlation was observed between
IGHV mutational status and intensity of BCR-induced
responses (not shown).
Inhibition of JNK suppresses both BCR-induced EGR-1
upregulation and cell survival
Since EGR-1 has been described as a downstream target of
JNK activation in various cellular models, we analyzed in
MCL the involvement of JNK in the BCR-induced
Figure 1 Kinetics of BCR-induced expressions of EGR-1 and c-MYC in MCL cell lines and primary MCL cells. (A) Kinetics of BCR-induced
mRNA expression of EGR-1 and c-MYC in Granta-519 and HBL-2 cell lines. 3×106 cells/ml were stimulated with 10 μg/ml of immobilized anti-IgM
antibody for 15 min, 30 min, 1 h, 3 h and 6 h. EGR-1 and c-MYC expressions were analyzed by qRT-PCR. (B) Induction of EGR-1 protein upon BCR
engagement was confirmed by western-blot. (C) The same experiments were performed on primary patients’ cells. EGR-1 and c-MYC expressions
were analyzed by qRT-PCR (left panel) and western-blot (right panels). (D) EGR-1 and c-MYC mRNA expressions upon anti-IgM stimulation (1 h)
were analyzed by qRT-PCR from 7 patients’ samples (UPN2, 3, 4, 5, 6, 7 and 8). Fold increase of mRNA level were calculated compared with
unstimulated cells in all experiments. All measurements were done in duplicate and the mean is provided.
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upregulation of EGR-1 and its role on MCL cell survival. In
a characteristic patient sample (UPN9), basal JNK phosphor-
ylation was slightly detected and was further enhanced
following 5 min of BCR ligation with higher increase of
phospho-JNK p46 (Figure 2A). Moreover, increase of BCR-
induced phospho-JNK p46 was fully abolished in the pres-
ence of a selective inhibitor of JNK (SP600125, 20 μM)
(Figure 2A). Inhibition of JNK by SP600125 induced a rapid
down-regulation of EGR-1 mRNA expression in HBL-2 and
Granta-519 cells associated with a subsequent decrease of
EGR-1 protein (Figure 2B). Moreover, treatment with
SP600125 upon anti-IgM stimulation also led to a blockade
of BCR-induced EGR-1 upregulation in MCL cell lines
(HBL-2 and Granta-519) and in primary MCL cells (UPN1)
(Figure 2C). To confirm that EGR-1 was a downstream
target of JNK in response to BCR activation, anti-IgM-
stimulated HBL-2 cells were incubated with 5Z-7-
Oxozeanol, an inhibitor of the transforming growth
factor-β activated kinase-1 (TAK1) that is critical for
BCR-induced JNK activation in B cells [29]. As shown in
Additional file 2: Figure S1, treatment with 5Z-7-Oxozeanol
(0.5 μM) completely abrogated BCR-induced upregulation
of EGR-1. Overall, these results indicate that constitutive
and BCR-induced EGR-1 expressions are dependent on JNK
activation in MCL cells.
We next investigated the impact of JNK inhibition on
MCL cell survival. Treatment of HBL-2 and Granta-519
cells with SP600125 for 48 h increased apoptosis (from 27%
Figure 2 Basal and BCR-induced EGR-1 expressions are dependent on JNK activation. (A) Primary cells (UPN9) were pretreated with
SP600125 (10 μM) for 1 hour and then stimulated with soluble anti-IgM antibody (10 μg/ml) for 5 min. Basal and BCR-induced phosphorylation of
JNK (p54 and p46) were analyzed by western-blot. ns: non specific band. (B) Treatment with SP600125 led to a time-dependent decrease of
mRNA and protein EGR-1 levels in Granta-519 and HBL-2 cells. (C) Impact of SP600125 on BCR-induced EGR-1 expression. Granta-519, HBL-2 and
primary cells (UPN1) were pretreated with SP600125 for 1 h and then stimulated with immobilized anti-IgM antibody. EGR-1 mRNA and protein
levels were analyzed by qRT-PCR and western-blot respectively. Fold increase of mRNA level were calculated relative to unstimulated cells in all
experiments. All measurements were done in duplicate and the mean is provided.
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and 34% to 68% and 61% of apoptotic cells for HBL-2 and
Granta-519, respectively) (Figure 3A). A similar increase of
apoptosis was observed in MCL primary cells (36 ± 5% and
50 ± 3% for untreated and treated cells respectively, n=4)
(Figure 3B). Moreover, BCR engagement induced in most
cases a significant inhibition of spontaneous apoptosis
(p=0.039) that was abrogated by a treatment with SP600125
(p=0.009) (Figure 3B). To confirm the involvement of EGR-
1 in BCR-induced cell survival, MCL primary cells
transfected with EGR-1 siRNA were stimulated with anti-
IgM. As shown in Figure 3C, a reduction of 20% to 30% of
cell survival was observed as compared to transfection with
Figure 3 Targeting JNK and EGR-1 induces MCL apoptosis and decreases BCR-induced cell survival. (A) HBL-2 and Granta-519 cells were
treated with SP600125 for 48 h and apoptosis was measured by flow cytometry. Percentage of apoptotic cells corresponded to% of annexin V-
positive, including PI-negative and PI-positive cells. Mean ± SD of 2 independent experiments is represented. (B) Patients’ cells (UPN1, 2, 8 and
11) were stimulated with immobilized anti-IgM for 24 h with or without SP600125 (10 μM) and the percentage of apoptotic cells was determined
by flow cytometry after gating on CD19+ cells (left panel). All measurements were done in duplicate and the mean is provided. Results are also
shown as median ± quartile (box) ± SE (bars) (n=4) (right panel). Differences between groups were determined using the paired Student t test. (C)
Jeko-1 cells were transfected either with control siRNA (Ctrl1) or EGR-1 siRNA and EGR1 protein level was determined by western-blot after 72 h
of culture (left panel). Primary MCL cells (UPN9) were transfected either with controls siRNA (Ctrl1, Ctrl2) or EGR-1 siRNA and subsequently
stimulated with anti-IgM for 24 h or left unstimulated (right panel). Percentage of apoptotic cells was normalized to unstimulated cells and
calculated as follows: [(% apoptosis BCR stimulated cells -% apoptosis BCR-unstimulated cells) / (% apoptosis BCR-unstimulated cells)] x100. All
measurements were done in duplicate and the mean value is provided.
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control siRNA. Collectively, these results indicate that EGR-
1 is a downstream target of JNK in MCL cells and that JNK
promoted constitutive and BCR-induced cell survival in
MCL implicating notably EGR-1 induction.
Inhibition of LYN activity is associated with an increase of
apoptosis in MCL cells
The BCR signal is initially transmitted by LYN kinase
leading to activation of various signaling pathways
including JNK. We therefore evaluated the activation
status of LYN in MCL cells and its involvement in cell
survival. Using an anti-phospho-SFK recognizing the
catalytic site of several Src kinases among which the
Tyr397 of LYN, we detected in 9 out of 10 UPN cases
tested (UPN 1,3,5,7,8,9,10,13,14) such a specific signal to
variable extents of constitutive phosphorylation forming
a 53–56 kDa doublet (Figure 4A and Additional file 3:
Figure S2). We confirmed that this doublet corresponded
to phospho-LYN by an immunoprecipitation assay using
an anti-LYN antibody (Figure 4B). Considering the consti-
tutive activation of LYN in MCL cells, we next evaluated
the impact of PP2, a synthetic pyrazolopyrimidine select-
ive inhibitor of SFK, and dasatinib (BMS-354825), an oral
multi kinase inhibitor which also inhibits the trans-
autophosphorylation of the active Tyr397 residue of LYN
[30]. Treatment of primary cells with PP2 or dasatinib led
to a dose-dependent decrease of Tyr397 LYN phosphoryl-
ation and complete inhibition was achieved up to 10 μM
and 100nM for PP2 and dasatinib respectively (Figure 4C).
Inhibition of phospho-Tyr397 LYN by PP2 was associated
with a significant and dose-dependent increase of apop-
tosis rate (from 49±4% to 67±3% apoptotic cells for un-
treated and 24 h treated (10 μM) cells respectively;
p=0.006; n=6) (Figure 4D). Treatment with dasatinib for
24 h also led to a significant and dose-dependent increase
of apoptosis (from 46±5% to 64±5% apoptotic cells for un-
treated and treated (100nM) cells, respectively; p=0.0001;
n=7) (Figure 4E). Remarkably, dasatinib had little apop-
tosis effect on phospho-Tyr397 LYN-negative cells
(UPN4) at a concentration up to 200nM (Figure 4E, top
panel). Altogether, these results indicate that MCL cells
display a constitutive phosphorylation of BCR-associated
LYN and that treatment with dasatinib or PP2 suppressed
LYN activation and increased spontaneous apoptosis.
Inhibition of the BCR-induced LYN phosphorylation by
PP2 or dasatinib is associated with a suppression of BCR-
mediated cell survival
Since PP2 and dasatinib efficiently blocked activation of
BCR-associated LYN in MCL cells, we next evaluated
the impact of these compounds on JNK phosphorylation,
EGR-1 expression and on cell survival upon BCR en-
gagement. As shown in Figure 5A, a strong increase of
phospho-Tyr397 LYN was observed in response to BCR
ligation (lane 1 compared to lane 4) and treatment with
dasatinib (100nM) completely blocked this effect while
SP600125 that affect JNK did not. Similarly, PP2
decreased BCR-induced phospho-Tyr397 LYN in pri-
mary MCL cells (Figure 5B). Dasatinib also reduced
BCR-induced phospho-JNK p46 (Figure 5C, lane 1
compared to lane 3 and lane 4 compared to lane 6),
positioning JNK as a downstream target of LYN in re-
sponse to BCR engagement. We next evaluated the im-
pact of dasatinib on basal and BCR-induced level of
EGR-1 as a target of JNK. As shown in Figure 5D (left
panels), dasatinib (100nM) decreased basal expression of
EGR1 mRNA and totally abrogated its upregulation in
response to BCR ligation (UPN3, UPN13). Dasatinib also
slightly decreased basal level of EGR1 protein and
blocked its BCR-induced upregulation (Figure 5D, right
panels and Additional file 4: Figure S3). Finally, we
evaluated the impact of PP2 and dasatinib treatment on
BCR-induced cell survival. Increasing concentrations of
dasatinib abrogated the BCR-induced survival response
in a dose-dependent manner and significantly suppressed
this survival signal in all UPN cases tested (from 34 ±6%
to 54±7% apoptotic cells for untreated and dasatinib-
treated BCR-activated cells, respectively; n=6; p<0.001)
(Figure 6A). Similarly, PP2 treatment also reduced or
abolished BCR-induced cell survival (Figure 6B). Overall,
these results highlight the importance of LYN, JNK and
EGR1 as intermediates of BCR signaling in mediating
survival signals in MCL cells and point out to the effi-
ciency of dasatinib in suppressing cell survival signal em-
anating from the BCR.
Discussion
In the present study, we showed that primary MCL cells
displayed a constitutive and BCR-induced activation of
LYN and that treatment with dasatinib or with a more
specific inhibitor of LYN suppressed both BCR-induced
JNK phosphorylation and EGR-1 upregulation and is
associated with a decrease of cell survival.
Recent studies have shown the importance of tonic
BCR signaling in survival of DLBCL cells [10] and CLL
cells [11] but few studies focused on the role of BCR sig-
naling in MCL cell survival [14,15]. We have previously
shown in MCL cells that BCR engagement induced a cell
survival signal through an IL6/IL10 autocrine dependent
activation of STAT3 [14]. To further identify early genes
involved in BCR-induced survival, we looked at the dif-
ferential gene expression upon BCR stimulation. We
evidenced that BCR engagement led to a rapid but tran-
sient induction of mRNA and protein levels of EGR-1.
EGR-1 is a zinc finger transcription factor whose expres-
sion has been described as directly dependent on antigen
receptor signaling [31,32]. EGR-1 is a downstream target
of JNK and it regulates the expression of several genes
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Figure 4 PP2 and dasatinib inhibit constitutive phosphorylation of LYN and induce apoptosis of primary MCL cells. (A) Constitutive
phosphorylation profiles of LYN in MCL patients’ samples. Phospho-Tyr397 LYN was detected using a pan phospho-src family antibody. The blots
were stripped and re-probed for total LYN. (B) Total proteins from HBL-2 cells were immunoprecipitated with an anti LYN antibody (Ig-LYN) or
with an irrelevant IgG control and immunobloted (IB) with either an anti-phosphotyrosine antibody (P-Tyr) or an anti-LYN antibody. (C) Primary
MCL cells (UPN3, UPN14) were treated with variable concentrations of PP2 (2 to 20 μM) or dasatinib (1 to 200nM) for 2 h. Phospho-Tyr397 LYN
and LYN total were analyzed by western-blot. (D) Primary MCL cells were treated with various concentrations of PP2 (UPN3, top panel) or 10 μM
of PP2 (UPN 1-3-7-8-9-14, middle panel) for 24 h and apoptosis was measured by flow cytometry after gating on CD19+ cells. All measurements
were done in duplicate and the mean is provided. Results are also shown as median ± quartile (box) ± SE (bars) bottom panel). Differences
between groups were determined using the paired Student t test. (E) Primary MCL cells were treated with dasatinib for 24 h with various
concentrations (top panel) or with 100nM (middle panel). Apoptosis was measured as described above. Results are also shown as median ±
quartile (box) ± SE (bars) bottom panel).
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Figure 5 PP2 and dasatinib inhibit BCR-induced LYN and JNK activation and EGR-1 upregulation. (A) Patients’ cells (UPN9) were
pretreated with dasatinib (100nM) or SP600125 (10 μM) for 1 h and stimulated for 5 min or 15 min with soluble anti-IgM (10 μg/ml). Phospho-
Tyr397 LYN was detected using a pan phospho-src family antibody. (B) The same experiment was done with PP2 (10 μM) on UPN 9 and UPN 13
under the same conditions of BCR stimulation for 10 min. Lines 1 and 2 have to be compared to evidence the effect of PP2 on the constitutive
level of phosphorylation for Lyn. Similarly lines 3 and 4 reflect this effect upon BCR stimulation. (C) BCR-induced phospho-JNK (p54 and p46) was
analyzed under treatment with dasatinib (100nM) or SP600125 (10 μM) used herein as a positive control of phospho-JNK inhibition. (D) Impact of
dasatinib on BCR-induced EGR-1 expression. MCL cells were pretreated with various concentrations of dasatinib as indicated and stimulated with
immobilized anti-IgM. EGR-1 mRNA and protein were analyzed by qRT-PCR at 1 h of stimulation (left panel) and western-blot at 3 h of stimulation
(right panel). Relative mRNA expression was calculated compared with unstimulated cells.
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like CD44, NF-kB1, thymidine kinase, cyclin D1 and
platelet-derived growth factor that are important for cell
survival and proliferation [23,33-35]. We thus evaluated
the role of EGR-1 in MCL cell survival and showed that
inhibition of JNK by SP600125 induced a decrease
of constitutive and BCR-induced EGR-1 expression,
associated with an increase of apoptosis and a suppres-
sion of BCR-induced survival. We confirmed the JNK-
dependent upregulation of EGR-1 by blocking the activ-
ity of TAK1, the upstream activator of JNK, which was
Figure 6 PP2 and dasatinib suppress BCR-induced cell survival. (A) Primary MCL cells (UPN3) were either left untreated or stimulated for
24 h with an anti-IgM antibody in the presence or in the absence of various concentrations of dasatinib (10 to 200nM) (top panel). Apoptosis
rates (Annexin V +/PI+ cells) were measured by flow cytometry after gating on CD19+ cells. For each BCR-stimulated condition (± dasatinib), the
percentage of apoptotic cells was normalized to unstimulated cells and calculated as follows: [(% apoptosis BCR stimulated cells -% apoptosis
BCR-unstimulated cells) / (% apoptosis BCR-unstimulated cells)] x100. Middle panel: Apoptosis rates from 6 MCL cases were measured from
unstimulated or BCR-stimulated cells (24 h) either in absence or presence of 10 nM dasatinib. All measurements were done in duplicate and the
mean is provided. Results are also shown as median ± quartile (box) ± SE (bars) (n=6) (bottom panel). Differences between groups were
determined using the paired Student t test. (B) Primary cells were treated with PP2 according to the same protocol described in (A).
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recently described to play an essential role in MCL sur-
vival [36]. Our results indicate that in MCL cells, EGR-1
is a downstream target of BCR signaling and its expres-
sion can be enhanced in response to antigen stimulation
leading to cell survival. In addition to EGR-1, we
observed that the BCR engagement also led to an in-
crease of c-MYC in patients’ cells only. This differential
response between cell lines and primary cells might re-
flect higher levels of c-MYC expression in cell lines as
compared to patient’s cells [37]. Cell lines might there-
fore become unresponsive to further stimulation
through the BCR. The delayed kinetic induction of c-
Myc as compared to EGR-1 in patient’s cells might argue
for a latter induction of c-Myc. Whether this induction
is related to expression of EGR-1 as proposed in CLL
[38] and BKS2 cells activated by CpG ODN [39] remains
to be determined. Nevertheless, our results suggest that
EGR-1 and c-MYC upregulations could play an essential
role in BCR-induced survival of MCL cells.
The importance of BCR signaling in MCL was recently
investigated using a high-throughput phospho-proteomic
technique which identified more than 300 tyrosine-
phosphorylated proteins [15]. The most abundant peptides
were part of proteins constituting the BCR-associated
signalosome. Among them, the kinases LYN and SYK were
found to be constitutively strongly phosphorylated, thus
reflecting an active BCR signaling even in absence of anti-
gen stimulation. The importance of the BCR signaling in
MCL was also suggested through the activation of SYK
probably due to a constitutively activated signalosome
made of LYN and CSK-binding protein/phosphoprotein
associated with glycosphingolipid-enriched microdomains
(Cbp/PAG) membrane adaptor [6,40]. In the present study,
we showed in a subset of primary MCL cells that LYN was
in a constitutively active form as revealed by phosphoryl-
ation of the active Tyr397 LYN residue. LYN is believed to
be a key component of cell membrane lipid rafts. Moreover,
a subset of transmembrane proteins with aberrant expres-
sion was identified in MCL plasma membranes [41]. In
particular, Cbp/PAG that participates to the negative regu-
lation of LYN in resting B cells through CSK recruitment
was underexpressed in MCL primary cells compared to
normal B cells. This low expression of Cbp/PAG could thus
contribute to the constitutive activation of LYN in MCL
cells.
Dasatinib, a dual BCR/ABL and SFK inhibitor, has
demonstrated its efficacy in inhibiting cell proliferation
of lymphoma B cells exhibiting a constitutive activation
of Src kinase. Yang et al. demonstrated that inhibition of
the Src-SYK-PLCg2 pathway by dasatinib induced G1 ar-
rest in DLBCL [42]. In the present study, we evidenced a
constitutive and BCR-induced phosphorylation of LYN,
thus justifying the rationale to evaluate the impact of
dasatinib in MCL cell survival. We showed that
dasatinib, which targeted the ATP binding pocket of
LYN [30], inhibited phosphorylation of Tyr397 LYN
probably by blocking its trans-autophosphorylation. .We
also showed for the first time that dasatinib induced
apoptosis of primary MCL cells and suppressed BCR-
induced survival after antigen-triggering at nanomolar
range. Of interest, the concentration levels of dasatinib
(100nM) required to induce in vitro MCL cell apoptosis
are in agreement with clinically achievable doses [43].
A phase II study of dasatinib in relapsed or refractory
CLL showed partial responses in 3 of 15 patients and
among the remaining 12 patients, five patients had
nodal responses. The investigators thus concluded that
dasatinib as a single agent had activity in relapsed and
refractory CLL [44]. A phase I/II study of dasatinib is
currently conducted by recruiting patients in relapsed or
refractory non-hodgkin’s lymphoma (NHL) including
mantle cell lymphoma (NCT00550615).
Conclusion
In conclusion, this study performed on primary MCL
lymphocytes evidenced a dysregulation of early BCR sig-
naling characterized by a constitutive LYN phosphoryl-
ation which can be enhanced in response to BCR
engagement. Furthermore, targeting proximal BCR-
associated kinases efficiently induced apoptosis of MCL
cells. Thus, inhibition of LYN kinase and downstream
JNK/EGR-1 pathway could be a new therapeutic strategy
in MCL to overcome pro-survival signal emanating from
the BCR.
Methods
MCL samples and cell lines
Peripheral blood mononuclear cells were obtained from 14
MCL leukemic patients by Ficoll-Hypaque density gradient
(Stem Cell Technologies, Grenoble, France). Lymphocytosis
was greater than 8.0×109/L and 10 out of 14 samples
contained at least 80% of B lymphocytes (Additional file 5:
Table S1). All B lymphocytes are monoclonal tumor B cells
as evidenced through flow cytometry phenotyping of the
surface immunoglobulin light chain (monotypic kappa or
lambda). Seven cases (7/14) showed mutated IGHV and
none of them displayed mutation in ITAM sequences of
CD79B. The diagnosis of MCL was ascertained by
immunophenotyping, cytogenetic and FISH analysis of t
(11;14) and overexpression of cyclin D1 was detected by
competitive RT-PCR according to the World Health
Organization classification. All patients were homoge-
neously treated in a prospective trial of the GOELAMS
group “Lymphome du manteau 2006 SA” [45]. All patients
were provided written informed consent, validated by the
Ethics Committee from the GOELAMS group, in accord-
ance with the Declaration of Helsinki. Patients usually
received treatment very quickly after sampling, making it
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difficulties to repeat all experiments several times on the
same sample. Jeko-1, and Granta-519 cell lines were
purchased from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunshwieig, Germany) and
the HBL-2 cell line was a generous gift from Dr B. Sola
(Caen, France) [46].
Patients’ cells were either used freshly isolated or
cryopreserved in liquid nitrogen in the presence of 10%
dimethyl sulfoxide and 20% heat-inactivated FCS. MCL
leukemic cells (3 × 106 cells/ml) were cultured in
complete RPMI 1640 medium supplemented with 10%
heat-inactivated foetal calf serum. Jeko-1, HBL-2 and
Granta-519 cell lines were maintained in culture in the
same media. For BCR stimulation, plates were pre-
coated with rabbit anti-human IgM antibody (10 μg/mL;
Jackson ImmunoResearch, Baltimore, MD) as previously
described [14] or the anti-IgM antibody was added to
the culture medium at the same concentration for short
stimulation time.
Antibodies and reagents
Antibodies to EGR-1 (mAb 44D5), c-MYC (mAb 9B11),
phospho-Src family (mAb 100 F9) also reactive with
phospho-Tyr397 LYN (catalytic site) and phospho-JNK
(Thr183/Tyr185) were from Cell Signaling (Beverley,
MA). Monoclonal mouse antibody (H-6) and polyclonal
rabbit antibody (44) to LYN were from Santa-Cruz (Santa
Cruz, CA). Anti-phosphotyrosine monoclonal antibody
(clone 4 G10) was from Millipore (Billerica, MA).
Dasatinib (Clini Sciences, Montrouge, France) was used at
100nM, unless otherwise stated. JNK inhibitor SP600125
and PP2 (4-Amino-3-(4-chlorophenyl)-1-(t-butyl)-1H-
pyrazolo[3,4-d]pyrimidine) was from Sigma (Saint
Quentin Fallavier, France) and (5Z)-7-Oxozeaenol (TAK1
inhibitor) was from Tocris Bioscience (Bristol, UK).
RT2 profiler PCR arrays
Tumor B-lymphocytes from MCL patients were purified
by the RosetteSepW Human B Cell Enrichment Cocktail
(Stemcell technologies, Grenoble, France). Cells were
cultured for 3 hours upon BCR stimulation or left un-
treated. Total RNA were extracted and analyzed with
“p53 signaling pathway” array (SA Biosciences PAHS-
027) according to the manufacturer’s instructions (SA
Biosciences, Frederick, MD) with an Applied Biosystems
7500 Fast Real-Time PCR Systems. Each gene expression
was normalized to the mean Ct values from the
four housekeeping genes available in the PCR array
(β2-microglobulin, β-actin ribosomal protein L13A,
hypoxanthine phosphorybosyl transferase-1 and β-actin),
then normalized to unstimulated control cells to deter-
mine the fold-change. Relative fold change of expression
was calculated by the ΔΔCt method and the values are
expressed as 2-ΔΔCt. All points were done in duplicate.
Apoptosis assay
Cell apoptosis was evaluated using flow cytometry
(FACSCantoTM II Becton Dickinson) on leukemic MCL
PBMC after gating on CD19+ cells using Annexin V-FITC
and propidium iodide staining (BD Biosciences, San Jose,
CA). Percentage of apoptotic cells corresponded to% of
annexin V-positive, including PI-negative and PI-positive
cells. All measurements were done in duplicate and the
mean is indicated.
Quantification of EGR-1 and c-MYC mRNA by qRT-PCR
RNA from unstimulated or anti-IgM stimulated cells
were extracted using RNeasy Mini kit (QIAGEN)
and EGR-1 and c-MYC expressions were analyzed by
qRT-PCR using SYBR Green reagents. Results were
normalized to the mean Ct values from cyclophilin A
housekeeping gene then normalized to unstimulated
control cells to determine the fold change. Relative fold
change of expression was calculated by the ΔΔCt
method and the values are expressed as 2 -ΔΔCt. All
points were done in duplicate. The primers used for
amplification (Sigma-Aldrich) were as follows:
EGR-1 forward primer
(50CGAGCAGCCCTACGAGCACCTGAC30),
EGR-1 reverse primer
(50TGCGCAGCTCAGGGGTGGGCTCTG30),
c-MYC forward primer
(50GCTGCTTAGACGCTGGATTTTT30),
c-MYC reverse primer
(50ACCGAGTCGTAGTCGAGGTCAT30),
cyclophilin A forward primer
(50GCACTGGAGAGAAAGGATTTGG30) and
cyclophilin A reverse primer
(50AGTGCCATTATGGCGTGTGA30).
Western blotting and immunoprecipitation
Total protein extracts from 3×106 MCL cells (PBMC) were
separated on 10% polyacrylamide denaturing gel, transferred
to a nitrocellulose membrane and incubated overnight with
the appropriate antibody followed by a secondary horserad-
ish peroxidase-conjugated antibody (Bio-Rad). Detec-
tion was performed using ECL (Amersham Biosciences,
Buckinghamshire, UK) and autoradiography (Biomax,
Kodak, Rochester, USA). For LYN immunoprecipitation,
HBL-2 cells were lysed in 1% Nonidet P-40 (NP-40) lysis
buffer for 30 minutes on ice. Insoluble material was
removed by centrifugation at 27 000 g for 10 minutes at
4°C and soluble proteins were immunoprecipitated with a
rabbit anti-LYN (H-6) antibody for 2 hours at 4°C.
Immunocomplexes were solubilized in SDS sample buffer,
analyzed on SDS-PAGE, transferred and subjected to im-
munoblotting as described above using either a mouse anti-
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phosphotyrosine antibody (clone 4 G10) or a mouse anti-
LYN (44) antibody.
siRNA assay
Three million cells were resuspended in 100 μL of
Human B Cell Lymphoma NucleofectorW Kit (Amaxa)
containing either 1 μM of EGR-1 siRNA (On-Target
plus SMART pool Human EGR-1, Dharmacon) or
1 μM of control siRNA (Ctrl1: On-Target plus non-
targeting pool; Ctrl2: On-target plus non-targeting
siRNA#1; Dharmacon). Cells were transfected in a
Nucleofector II device (Lonza) by using U-015 pro-
gram, transferred to culture plates and western blot
and apoptosis assays were performed as described
above.
Statistical analyses
Differences between groups were determined using the
Student’s t test. Statistical analyses were performed using
GraphPad Prism software (San Diego, CA). P values
below 0.05 were considered statistically significant.
Additional files
Additional file 1: Table S2. Differentially expressed genes in BCR-
stimulated MCL cells (3 h) compared with unstimulated cells.
Additional file 2: Figure S1. Inhibition of TAK1 protein by (5Z)-7-
Oxozeaenol suppressed BCR-induced EGR1 expression. HBL2 cells were
pretreated with (5Z)-7-Oxozeaenol (5Z-7-oxo) (0.3 and 0.5 μM) for 1 h
and then stimulated with immobilized anti-IgM (10 μg/ml). Total protein
extracts were analysed by western-blot for EGR1 expression.
Additional file 3: Figure S2. Constitutive phosphorylation of LYN in
primary MCL cells. Total protein from UPN1, UPN5, UPN13 and UPN14
were extracted and analysed by western blot. Phospho-Tyr397 LYN was
detected using a pan phospho-src family antibody. The blots were
stripped and re-probed for total LYN.
Additional file 4: Figure S3. Dasatinib treatment suppresses BCR-
induced upregulation of EGR-1 protein. HBL-2 cells were pretreated (1 h)
with various concentrations of Dasatinib (1nM-200nM) and stimulated
with immobilized anti-IgM for 1 h (anti-IgM) or left unstimulated (−).
EGR1 protein level was then analysed by western blot.
Additional file 5: Table S1. Characteristics of the 14 MCL cases (UPN).
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